What AI says about Zolgensma
Zolgensma is a one-time gene replacement therapy for children under 2 years old with spinal muscular atrophy.
AI mentioned Zolgensma from October 2025 to June 2026.
Questions and answers
- AI picks most
- What are the latest affordable advancements in biopharma for treating rare diseases?AI picks U.S. Food and Drug Administration (FDA) and 6 more about as often
Excerpts where Zolgensma appeared in the AI's answer
Zolgensma in AI answers
What are the latest affordable advancements in biopharma for treating rare diseases?
ChatGPTChatGPT· Jun 2, 2026
New manufacturing methods are reducing production costs, which historically made therapies like Zolgensma extremely expensive (~$2 million per dose).
Google AI ModeGoogle AI ModeNo answer mentioning Zolgensma
Brands AI mentions
AI mentioned Zolgensma alongside CRISPR Therapeutics, Moderna, and Sarepta Therapeutics.
